{"name":"GammaDelta Therapeutics Limited","slug":"gammadelta-therapeutics-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWdGRTVzOWhMVlJyUkU3eXc2SjFDbl9lbm93VmphbEtwRXBybklIbjB1Njhvdk5KaXdDNkRURXdWaTlySWxaaUFuZVFjZlZPYVR4cWRNRkpzeUlKRjJsYVlUX0pIdWpsTkJRWlJLNm85ZHFZZG9ndHlSRy1xQXFNb3RWX0lpME9SOEJ1VFNCVzREWTA?oc=5","date":"2025-12-17","type":"pipeline","source":"Insightace Analytic","summary":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNVzV1aFpGRmFTVVI5Qjg2N1FHYnV4VTdlOHBvYlNKUkZyVDF4THJWWUdCYkdiYVlrUzQwVHlDd2tkdVpBbHlOOXpTdUR0WUFNNlBNWGhTUzJJckx6QkhTQV9GNEJzQVZGUk5RV003bTFtcGJIVjRtNDJOOGJqeldoR2s0QnViUk1pNFM5YS1XLVd1ejdMVDNkQUFLYmpVcjkyb1dHVm9GcWFjUXBrZXRtYzJn?oc=5","date":"2025-10-30","type":"trial","source":"Fierce Biotech","summary":"Takeda drops AstraZeneca-partnered neurological program after phase 2 failure - Fierce Biotech","headline":"Takeda drops AstraZeneca-partnered neurological program after phase 2 failure","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPR01YTlpyc1dtWk5Ya3BtTnhKUlZLdWR3S1ctMDJubUN0M3lPRnJNemVRb2h1akN5Q05UMEszUF84OWc1bFB0YTZ5TEN3cU9OcTBxZFFfS2dwNW9VbnpCTnlTQWgtcjBObGUxbGI2Z1VkTllWQm1sdVRydjNhcDZabXU5MUcxOXFFckxyNUw4dDJmVDVBMzF4SnlHZ3ljcWNkc3h1QUh1QmhOdUgzMERPMTh3?oc=5","date":"2025-10-03","type":"pipeline","source":"European Pharmaceutical Review","summary":"Takeda withdraws from clinical cell therapy activities - European Pharmaceutical Review","headline":"Takeda withdraws from clinical cell therapy activities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOT2k1RWlodlFkR0YyRnNEUUFuS2Jtc0YtbXc0aXhJLUpObmZwU0pxaHg0cDlYZmthS2RxRDM1djdUaUJEZjVzNWJwcGZzcmRJbG5oUTR3ZXZBc3QxUTBYcGRZRzhyTWVQNlhKVjVQMGVzUV85MWJoVlFzQXhPdTlra1Y1Yw?oc=5","date":"2025-10-02","type":"pipeline","source":"BioWorld News","summary":"Takeda ditches cell therapy business - BioWorld News","headline":"Takeda ditches cell therapy business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOYW84X2VwOU1jRUIwc21NaXl1RGlPdTlpSVNFWnRvNHBWNHczZ0FKU0U4Rl9JUnBnOHpiOGl4X3BLT2lpMHA2UUNyQ2g1LUF4d0lERW1QOWxhQzFoRDMxbzZGbjdxMU1KV1VGWTJCOVF3MHR1SVhpeUFRWk9tRUNDSmJ1NmhnZw?oc=5","date":"2025-10-02","type":"trial","source":"Clinical Trials Arena","summary":"Takeda walks away from cell therapy in priority U-turn - Clinical Trials Arena","headline":"Takeda walks away from cell therapy in priority U-turn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPeWFEVUhTNlQ4T0xqUTBPekhzV21vdVhrTUFTdmoySXJ6eTJQZVlBc2I0ckE4aG53Y3hIY1FrREhmR1ZvRHZveEFYM1g2a1lMMTY5NWlrY1lxYXlOSm9hVlNOUE5kQmxNSmNZWHU0ZHNqZUtzUFBicDVhX0xFWExGYVVSVnU?oc=5","date":"2025-10-02","type":"trial","source":"Oncology Pipeline","summary":"Takeda’s cancer prospects dim further | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Takeda’s cancer prospects dim further | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNMVV0MzI1VUlkSDdnNnlHbV82SXNaNVpWR1FoTHZOQm1pM3NsNmE0SlozSmh5ZU5nT1l6dHNGOVRKMkVfY0d4UkwzWW4xamVfYXdrZ05HV3NDeDItb2E5RDdhVWE5RVQ2OGw4dFVOeHRuWlQ3dzlsWVRMM1I2Tl9hS19R?oc=5","date":"2025-10-02","type":"pipeline","source":"Yahoo Finance","summary":"Takeda walks away from cell therapy in priority U-turn - Yahoo Finance","headline":"Takeda walks away from cell therapy in priority U-turn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQR0QwMHpiR1hhbm1qUDRRRkJzRlVwZUpCQjJ5NVY5TC1oWm5fTWx6TEcteWlTbDZqaDlQNzJ0eUJndW9qSTFIU0k3OUJOUnc1aTlDMVJHMng3OXhHcFlwaVl3SlZJdnYyeGJyR0RxdUxJMFlYU3ZwRVZfZFhFX2FrTzFzaGgzZEswOTNjbU5KOHVQQnZ4cVE?oc=5","date":"2025-10-02","type":"pipeline","source":"The Pharma Letter","summary":"Takeda to pull out of cell therapy development - The Pharma Letter","headline":"Takeda to pull out of cell therapy development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNV3dzZVc4VlVQbmRJTU1sSmVNeWFBc3J6clRkVGhQSTR1dkl3RlJDTktISS1MWHdDR0RlY28tUGktb0lpMGJYTVJWeExMb2NvMTUzQm1qek1BSmJKOEY0cHh5b2hFdDRyU0VQZ1k2NHpoN0JSUldKRUVYTzNPbHUtLUQ1ZmxROVpmRktiT2d4eTdva2NrX0pMWTNOWm9EWFk4SWJKdFpSTXduWXBBc0ZGSTF2QVFObjNGeVJrMUtLbS1IT3M1Z1lhMjl2UF9rVGkwbGpwQjRPM3N3SDJLaW5fQjByY0V3cHJHb3ZJRmNadzJ1eElHUVdJakRWdFlOZ0R0Y1djdHhoQ3dPUUplWjNGNWhPWkZyclpVNlBBaHNBNGJQaUZXRnlZ?oc=5","date":"2022-07-20","type":"deal","source":"PPF Group","summary":"Takeda to acquire GammaDelta Therapeutics to develop γδ T cell therapies - PPF Group","headline":"Takeda to acquire GammaDelta Therapeutics to develop γδ T cell therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxOcS1pUWVWUndDeTR6VEV3N3RzeVFsRWtQbVlJT0J1NVlhSkFRWk1CQmhJcjIxVlVKcXV3MmZTaXBKeWs0T1o1MXpPTnBCTEdaVnR4RlNZLTdVWWxUNEZWT1VqelI3a2hzazRHUWNEZDZSWEI2VnpTckNlNHFKWXdCR0hjdW5SZVdKcFlaZnlYdVJzNGk4MWJSeHVpY2Z4SWFuU3pRRG0xaDV2bXh3c1pVYkhGbzVfbFJQNWRJa0JvZ3cwc1kyMkEwdFBWVXpTX3RFd05QeXpGWHg2czctakttNWlDb2VCVTJ3bndZWl9Ic1lHUmcyb25oQ3BHX3Z3S2lEd3NnN1kzMA?oc=5","date":"2022-01-10","type":"deal","source":"Business Wire","summary":"Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors - Business Wire","headline":"Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tu","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE1BUmdkc0Y4bHZycWYwc2xxMDFubHFYS1Q5ZGtheThVeUY2ZWh2d0VwVVE2RmY3aWpYOWZ3MmxJSlB3ZUk0R05jdTFObURjalFhMTZ4Yml5ellkUTdTVXp3QWpFTnVCZUlEQUx6cg?oc=5","date":"2021-10-28","type":"deal","source":"kcl.ac.uk","summary":"King's spin-out acquired by Takeda - kcl.ac.uk","headline":"King's spin-out acquired by Takeda","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQSUtrVkswQ0pPSHY2TW1Ic0VxMHF5SGY0a1F2NnZTNkREZ010UWt2by0wME9VckxCaGRtQm1EbVhCaGd2R3QzZmFJYWhWZ0FjVm5yRmQtbHlhM3lsMFU3OW1WOHFnd29sSkg2NmVlY1U3MmNUU2hjWWxQUG5nZkNzZzNhcmtnU3U4ZXBTbF9Md3NsVlM4YWVWS0YzRU55NlgzLUxhNHNXSzRweUU0bUZyU3Jyaw?oc=5","date":"2021-10-27","type":"deal","source":"drugdiscoverytrends.com","summary":"Takeda plans to acquire GammaDelta for its solid tumor drug pipeline - drugdiscoverytrends.com","headline":"Takeda plans to acquire GammaDelta for its solid tumor drug pipeline","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}